Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.64 |
| ▸ | HTR1B | P28222 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | HTR6 | P50406 | 2/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10650990 | 1.00 | HTR2A (0.64) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL2198661 | 1.00 | HTR2A (0.64) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL7592101 | 0.88 | HTR2A (0.60) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL8742343 | 0.85 | HTR2A (0.57) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL20879351 | 0.84 | HTR2A (0.64) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL22012838 | 0.81 | HTR2A (0.74) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL24991334 | 0.81 | SMN1; SMN2 (0.63) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL12563613 | 0.81 | HTR2A (0.64) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL8792007 | 0.81 | HTR2A (0.64) | HTR2AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL14217025 | 0.80 | HTR2A (0.59) | HTR2AHTR1DHTR1BHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0081877-B1 | LH-RH ANTAGONISTS | COY, David Howard (US) | 1986-04-30 | — | — | EP | claimed |
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8357638-B2 | Oligonucleotide library encoding randomised peptides | ASTON UNIVERSITY (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8183202-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20090264313-A1 | Oligonucleotide library encoding randomised peptides | ASTON UNIVERSITY (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20070280939-A1 | Prostatic Acid Phosphatase Antigens | NOTTINGHAM TRENT UNIVERSITY, THE (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070243562-A1 | Lectins for Analyzing Sugar Chains and Method of Using the Same | SUMMIT GLYCORESEARCH CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070231855-A1 | Functional molecule and manufacturing method therefor | FUJITSU LIMITED (JP) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | GPR6, GALR3, NTSR1 | HTR2A 643/4885HTR1D 1116/4885HTR1B 344/4885 |
| US-20070280939-A1 | Prostatic Acid Phosphatase Antigens | ACP3, KLK3, PSAP | HTR2A 4826/4885HTR1D 4881/4885HTR1B 4874/4885 |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | MTPN, NISCH, VIP | HTR2A 2080/4885HTR1D 2471/4885HTR1B 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.